Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer

esmo - Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study

AI Summary: A randomized first‑line trial found that adding retifanlimab to standard chemotherapy meaningfully improved overall survival for patients with advanced squamous anal cancer, signaling a new immunotherapy-containing option where few exist. The data from the POD1UM‑303/InterAACT‑2 program offer clinicians a viable strategy to extend life without reinventing the wheel.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks

James P. Allison wins AACR lifetime achievement award / 7 wks

Metabolic enzyme linked to immunotherapy benefit; routing metabolites may boost response / 1 month

Atezolizumab plus FOLFOX improves DFS in Stage III dMMR colon cancer / 1 month

AstraZeneca’s in‑vivo CAR‑T yields early responses but raises safety questions / 2 months